SCHEMBL996641

SCHEMBL996641

CCC(C)NCCCCN

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.40
F13A1 P00488 2/20 0.40
CA2 P00918 2/20 0.40
CYP1A2 P05177 2/20 0.40
ALOX15 P16050 2/20 0.40
TSHR P16473 2/20 0.40
CA4 P22748 2/20 0.40
CA6 P23280 2/20 0.40
CA5A P35218 2/20 0.40
THPO P40225 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40
CA5B Q9Y2D0 2/20 0.40
CA1 P00915 1/20 0.40
CA3 P07451 1/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.40
MTOR P42345 1/20 0.40
ALDH1A1 P00352 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21799856 0.98 DNM1 (0.40) CA12F13A1CA2CYP1A2ALOX15
SCHEMBL21799870 0.98 DNM1 (0.40) CA12F13A1CA2CYP1A2ALOX15
SCHEMBL21799746 0.98 DNM1 (0.40) CA12F13A1CA2CYP1A2ALOX15
SCHEMBL21799669 0.98 DNM1 (0.40) CA12F13A1CA2CYP1A2ALOX15
SCHEMBL21799739 0.98 DNM1 (0.40) CA12F13A1CA2CYP1A2ALOX15
SCHEMBL21799872 0.98 DNM1 (0.40) CA12F13A1CA2CYP1A2ALOX15
SCHEMBL2701973 0.98 DNM1 (0.40) CA12F13A1CA2CYP1A2ALOX15
SCHEMBL21799947 0.98 DNM1 (0.40) CA12F13A1CA2CYP1A2ALOX15
SCHEMBL9472346 0.93
SCHEMBL30891548 0.87 ALDH1A1 (0.44) ALOX15TSHRALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025228982-A1 PROCESS FOR RECYCLING A COMPOSITION COMPRISING A POLY(UREA-URETHANE) POLYMER WITH HINDERED UREA BONDS BASF SE (DE) 2025-11-06 WO claimed
WO-2025228991-A1 RECYCLABLE POLY(UREA-URETHANE) SYSTEM BASF SE (DE) 2025-11-06 WO claimed
CN-113512029-B Preparation and application of substituted pyrazole compound containing pyrimidinamine 沈阳中化农药化工研发有限公司 2023-01-24 CN claimed
WO-2025228982-A1 PROCESS FOR RECYCLING A COMPOSITION COMPRISING A POLY(UREA-URETHANE) POLYMER WITH HINDERED UREA BONDS BASF SE (DE) 2025-11-06 WO disclosed
WO-2025228991-A1 RECYCLABLE POLY(UREA-URETHANE) SYSTEM BASF SE (DE) 2025-11-06 WO disclosed
EP-3623398-B1 RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER ASAHI CHEMICAL IND (JP) 2024-08-28 EP disclosed
CN-110603273-B Modified block copolymer, method for producing modified block copolymer, and resin composition 旭化成株式会社 2022-10-14 CN disclosed
US-11124593-B2 Modified block copolymer, method for producing modified block copolymer, and resin composition ASAHI KASEI KABUSHIKI KAISHA (JP) 2021-09-21 US disclosed
EP-3831372-A1 MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS Pathologica LLC (US) 2021-06-09 EP disclosed
US-20200199282-A1 Modified Block Copolymer, Method for Producing Modified Block Copolymer, and Resin Composition ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-06-25 US disclosed
EP-3623398-A1 MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION Asahi Kasei Kabushiki Kaisha (JP) 2020-03-18 EP disclosed
US-7432302-B2 Composition containing polyamine transport inhibitor and use thereof MEDIQUEST THERAPEUTICS, INC. (US) 2008-10-07 US disclosed
EP-1373185-A4 HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE MEDIQUEST THERAPEUTICS INC (US) 2005-12-07 EP disclosed
US-6963010-B2 Anticancer agents; osteoporosis; autoimmune disease MEDIQUEST THERAPEUTICS, INC. (US) 2005-11-08 US disclosed
US-20050245615-A1 Composition containing polyamine transport inhibitor and use thereof MEDIQUEST THERAPEUTICS, INC. (US) 2005-11-03 US disclosed
US-20050176828-A1 Hydrophobic polyamine analogs and methods for their use MEDIQUEST THERAPEUTICS, INC. (US) 2005-08-11 US disclosed
CN-1511137-A Hydrophobic polyamine analogs and methods of use thereof 麦迪凯斯特治疗学股份有限公司 2004-07-07 CN disclosed
EP-1373185-A2 HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE Mediquest Therapeutics, Inc. (US) 2004-01-02 EP disclosed
US-20030187276-A1 Hydrophobic polyamine analogs and methods for their use AMINEX THERAPEUTICS, INC. 2003-10-02 US disclosed
WO-2002053519-A2 HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE MEDIQUEST THERAPEUTICS, INC. (US) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187276-A1 Hydrophobic polyamine analogs and methods for their use SRM, SMS, HNMT CA12 3886/4885F13A1 2954/4885CA2 3736/4885
US-20050176828-A1 Hydrophobic polyamine analogs and methods for their use SRM, SMS, HNMT CA12 3886/4885F13A1 2954/4885CA2 3736/4885
US-20050245615-A1 Composition containing polyamine transport inhibitor and use thereof SLC7A1, SRM, SLC16A1 CA12 4107/4885F13A1 2277/4885CA2 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.